Breast cancers at all stages are defined by the structure of their genomes, researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.
Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...
A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now approved for use in Thailand.[1,2,3] ...
AZoLifeSciences on MSN2h
Researchers Uncover Genomic Drivers Behind Aggressive Breast CancerBreast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...
HealthDay on MSN4d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast CancerFor patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...
Verywell Health on MSN4d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer TypeThe FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...
The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback